Background and Objectives: Breast cancer is among the most common causes of cancer related mortality in women worldwide. Early detection and prompt diagnosis of tumor is the first step to prevent cancer-related morbid...Background and Objectives: Breast cancer is among the most common causes of cancer related mortality in women worldwide. Early detection and prompt diagnosis of tumor is the first step to prevent cancer-related morbidity and mortality, and a comprehensive understanding of the involved molecular mechanisms can greatly help in this respect. Breast cancer, like many other types of cancer, is caused by a combination of genetic and epigenetic changes such as inactivation of tumor suppressor genes. Materials and Methods: This study was performed on 40 breast cancer patients and 40 healthy controls. Quantitative real time reverse transcription polymerase chain reaction (real time qRT-PCR) was used to assess the expression of carcinoembryonic antigen (CEA) and mammaglobin mRNA in the peripheral blood of patients and healthy controls. The two groups were compared using t-test. Results: The two groups were not significantly different in terms of the mean age. Twenty-nine out of 40 cancer patients were positive for CEA mRNA and its sensitivity was calculated to be 72.5%. Twelve out of 40 healthy controls were positive for CEA mRNA. Twenty-six out of 40 patients were positive for mammaglobin mRNA indicative of 65% sensitivity while only five out of 40 healthy controls were positive for mammaglobin mRNA. Conclusion: Both CEA and mammaglobin mRNA had high sensitivity in cancer patients;thus, they can be used for screening and early detection of breast cancer patients. Further studies with larger sample sizes are required to confirm the current findings.展开更多
Objective： The aim of the study was to explore the individual detection significances of small breast epithelial mucin （SBEM） and human mammaglobin （hMAM） in peripheral blood （PB） of breast cancer patients. Met...Objective： The aim of the study was to explore the individual detection significances of small breast epithelial mucin （SBEM） and human mammaglobin （hMAM） in peripheral blood （PB） of breast cancer patients. Methods： SBEM and hMAM expressions in PB samples of 109 primary breast cancer patients were detected by flow cytometry （FCM） and RT- PCR. Relationship between the biomarkers＇ expression and prognostic parameters were analyzed. Results： SBEM and hMAM expressions in PB of breast cancer patients were much higher than those of healthy donors and other cancer patients. SBEM and hMAM expressed in 53.2% （50/94） and 39.4% （37/94） cases at stages I-III and expressed in 73.3% （11/15） and 46.7% （7/15） cases at stage IV respectively. SBEM and hMAM mRNA were only detected in PB samples of breast cancer patients, while no expression of them was found in that of healthy donors and other cancer patients. Conclusion： hMAM mRNA detection maybe helpful to predict hematogenous micrometastasis in ER-positive, well-differentiated breast cancers and SBEM mRNA detection maybe helpful to predict hematogenous micrometastasis in ER-negative, poody-differentiated breast cancers.展开更多
目的克隆人乳腺珠蛋白(hum an m amm aglob in,hM aM)基因,建立荧光定量PCR方法,探讨外周血hM aM mRNA的表达作为乳腺癌血行微小转移标志物的可能性。方法设计特异引物,用RT-PCR方法从乳腺癌组织扩增获得目的片段,利用T/A克隆将PCR产物...目的克隆人乳腺珠蛋白(hum an m amm aglob in,hM aM)基因,建立荧光定量PCR方法,探讨外周血hM aM mRNA的表达作为乳腺癌血行微小转移标志物的可能性。方法设计特异引物,用RT-PCR方法从乳腺癌组织扩增获得目的片段,利用T/A克隆将PCR产物插入pMD-18T载体;优化扩增条件,以pMD/M质粒制备标准曲线,建立FQ-PCR方法,对乳腺癌不同分期的患者(n=28),乳腺良性疾病患者(n=15),其他肿瘤患者(n=33)的外周血进行检测。结果成功获得hM aM基因并完成克隆,阳性克隆测序结果与预期序列一致;建立了FQ-PCR检测hM aM mRNA方法;28例乳腺癌病人中9例(32.1%)阳性(Ⅰ期4例,Ⅱ期3例,Ⅲ期1例,Ⅳ期1例),hM aM mRNA的表达与乳腺癌病理分期无关(χ2=0.5936;P>0.05);乳腺良性疾病组,其他肿瘤病人组及对照组外周血中均未检出hM aM mRNA。结论hM aM mRNA是乳腺癌特异性标志物,其外周血的表达可作为乳腺癌血行微小转移的指标。展开更多
文摘Background and Objectives: Breast cancer is among the most common causes of cancer related mortality in women worldwide. Early detection and prompt diagnosis of tumor is the first step to prevent cancer-related morbidity and mortality, and a comprehensive understanding of the involved molecular mechanisms can greatly help in this respect. Breast cancer, like many other types of cancer, is caused by a combination of genetic and epigenetic changes such as inactivation of tumor suppressor genes. Materials and Methods: This study was performed on 40 breast cancer patients and 40 healthy controls. Quantitative real time reverse transcription polymerase chain reaction (real time qRT-PCR) was used to assess the expression of carcinoembryonic antigen (CEA) and mammaglobin mRNA in the peripheral blood of patients and healthy controls. The two groups were compared using t-test. Results: The two groups were not significantly different in terms of the mean age. Twenty-nine out of 40 cancer patients were positive for CEA mRNA and its sensitivity was calculated to be 72.5%. Twelve out of 40 healthy controls were positive for CEA mRNA. Twenty-six out of 40 patients were positive for mammaglobin mRNA indicative of 65% sensitivity while only five out of 40 healthy controls were positive for mammaglobin mRNA. Conclusion: Both CEA and mammaglobin mRNA had high sensitivity in cancer patients;thus, they can be used for screening and early detection of breast cancer patients. Further studies with larger sample sizes are required to confirm the current findings.
文摘Objective： The aim of the study was to explore the individual detection significances of small breast epithelial mucin （SBEM） and human mammaglobin （hMAM） in peripheral blood （PB） of breast cancer patients. Methods： SBEM and hMAM expressions in PB samples of 109 primary breast cancer patients were detected by flow cytometry （FCM） and RT- PCR. Relationship between the biomarkers＇ expression and prognostic parameters were analyzed. Results： SBEM and hMAM expressions in PB of breast cancer patients were much higher than those of healthy donors and other cancer patients. SBEM and hMAM expressed in 53.2% （50/94） and 39.4% （37/94） cases at stages I-III and expressed in 73.3% （11/15） and 46.7% （7/15） cases at stage IV respectively. SBEM and hMAM mRNA were only detected in PB samples of breast cancer patients, while no expression of them was found in that of healthy donors and other cancer patients. Conclusion： hMAM mRNA detection maybe helpful to predict hematogenous micrometastasis in ER-positive, well-differentiated breast cancers and SBEM mRNA detection maybe helpful to predict hematogenous micrometastasis in ER-negative, poody-differentiated breast cancers.
文摘目的克隆人乳腺珠蛋白(hum an m amm aglob in,hM aM)基因,建立荧光定量PCR方法,探讨外周血hM aM mRNA的表达作为乳腺癌血行微小转移标志物的可能性。方法设计特异引物,用RT-PCR方法从乳腺癌组织扩增获得目的片段,利用T/A克隆将PCR产物插入pMD-18T载体;优化扩增条件,以pMD/M质粒制备标准曲线,建立FQ-PCR方法,对乳腺癌不同分期的患者(n=28),乳腺良性疾病患者(n=15),其他肿瘤患者(n=33)的外周血进行检测。结果成功获得hM aM基因并完成克隆,阳性克隆测序结果与预期序列一致;建立了FQ-PCR检测hM aM mRNA方法;28例乳腺癌病人中9例(32.1%)阳性(Ⅰ期4例,Ⅱ期3例,Ⅲ期1例,Ⅳ期1例),hM aM mRNA的表达与乳腺癌病理分期无关(χ2=0.5936;P>0.05);乳腺良性疾病组,其他肿瘤病人组及对照组外周血中均未检出hM aM mRNA。结论hM aM mRNA是乳腺癌特异性标志物,其外周血的表达可作为乳腺癌血行微小转移的指标。
